ITMI942512A0 - Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli selettivamente attive sul recettore periferico dei cannabinoidi - Google Patents

Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli selettivamente attive sul recettore periferico dei cannabinoidi

Info

Publication number
ITMI942512A0
ITMI942512A0 ITMI942512A ITMI942512A ITMI942512A0 IT MI942512 A0 ITMI942512 A0 IT MI942512A0 IT MI942512 A ITMI942512 A IT MI942512A IT MI942512 A ITMI942512 A IT MI942512A IT MI942512 A0 ITMI942512 A0 IT MI942512A0
Authority
IT
Italy
Prior art keywords
aminoalcohols
mono
therapeutic use
cannabinoid receptor
selectively active
Prior art date
Application number
ITMI942512A
Other languages
English (en)
Inventor
Valle Francesco Della
Alberta Leon
Gabriele Marcolongo
Silvana Lorenzi
Original Assignee
Lifegroup Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lifegroup Spa filed Critical Lifegroup Spa
Publication of ITMI942512A0 publication Critical patent/ITMI942512A0/it
Priority to ITMI942512A priority Critical patent/IT1271266B/it
Priority to US08/860,356 priority patent/US5990170A/en
Priority to CA002207850A priority patent/CA2207850C/en
Priority to JP51826596A priority patent/JP4216330B2/ja
Priority to PCT/EP1995/004927 priority patent/WO1996018391A2/en
Priority to EP95942142A priority patent/EP0799033A1/en
Priority to AU43442/96A priority patent/AU4344296A/en
Priority to IL11640095A priority patent/IL116400A0/xx
Publication of ITMI942512A1 publication Critical patent/ITMI942512A1/it
Application granted granted Critical
Publication of IT1271266B publication Critical patent/IT1271266B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ITMI942512A 1994-12-14 1994-12-14 Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi IT1271266B (it)

Priority Applications (8)

Application Number Priority Date Filing Date Title
ITMI942512A IT1271266B (it) 1994-12-14 1994-12-14 Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
PCT/EP1995/004927 WO1996018391A2 (en) 1994-12-14 1995-12-13 Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor
CA002207850A CA2207850C (en) 1994-12-14 1995-12-13 Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor
JP51826596A JP4216330B2 (ja) 1994-12-14 1995-12-13 末梢カンナビノイドレセプターで作用する薬物製造でのモノおよびビカルボン酸アミドの利用
US08/860,356 US5990170A (en) 1994-12-14 1995-12-13 Therapeutic use of mono and bicarboxylic acid amides active at the peripheral cannabinoid receptor
EP95942142A EP0799033A1 (en) 1994-12-14 1995-12-13 Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor
AU43442/96A AU4344296A (en) 1994-12-14 1995-12-13 Use of mono and bicarboxylic acid amides for the manufacture of a medicament active at the peripheral cannabinoid receptor
IL11640095A IL116400A0 (en) 1994-12-14 1995-12-14 Therapeutic use of mono and dicarboxylic acid amides with aminoalcohols or aminoethers in the manufacture of a medicament selectively active on the cannabinoid peripheral receptor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI942512A IT1271266B (it) 1994-12-14 1994-12-14 Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi

Publications (3)

Publication Number Publication Date
ITMI942512A0 true ITMI942512A0 (it) 1994-12-14
ITMI942512A1 ITMI942512A1 (it) 1996-06-14
IT1271266B IT1271266B (it) 1997-05-27

Family

ID=11369989

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI942512A IT1271266B (it) 1994-12-14 1994-12-14 Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi

Country Status (8)

Country Link
US (1) US5990170A (it)
EP (1) EP0799033A1 (it)
JP (1) JP4216330B2 (it)
AU (1) AU4344296A (it)
CA (1) CA2207850C (it)
IL (1) IL116400A0 (it)
IT (1) IT1271266B (it)
WO (1) WO1996018391A2 (it)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19706903A1 (de) * 1997-02-21 1998-08-27 Bayer Ag Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
CA2330681C (en) * 1998-05-29 2008-08-26 Andrea Giuffrida Control of pain with endogenous cannabinoids
IT1302264B1 (it) * 1998-09-24 2000-09-05 Innovet Italia Srl Derivati a struttura n-acil vanillinamidica in grado di attivare irecettori periferici dei cannabinoidi
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US6864285B1 (en) 1999-07-07 2005-03-08 Innovet Italia S.R.L. Covalent derivatives of alkanolamides of monocarboxylic and dicarboxylic acids functionally active on the CB2 cannabinoid receptor
ATE290858T1 (de) * 1999-08-06 2005-04-15 Innovet Italia Srl N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin
FR2800372B1 (fr) * 1999-11-03 2001-12-07 Sanofi Synthelabo Derives tricycliques d'acide 1-benzylpyrazole-3- carboxylique, leur preparation, les medicaments en contenant
US6410597B1 (en) * 2000-02-25 2002-06-25 Virginia Commonwealth University Hydroxyalkyl amide analogs of ceramide
AU2001264930A1 (en) * 2000-05-23 2001-12-03 The Regents Of The University Of California A novel treatment for cough
US20020137802A1 (en) * 2000-09-28 2002-09-26 Travis Craig R. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
US6541510B2 (en) * 2000-09-28 2003-04-01 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
US7067539B2 (en) * 2001-02-08 2006-06-27 Schering Corporation Cannabinoid receptor ligands
US7025992B2 (en) * 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
GB0104268D0 (en) * 2001-02-21 2001-04-11 Unilever Plc Antiperspirant or deodorant compositions
TWI238068B (en) 2001-03-06 2005-08-21 Kao Corp Composition for external application
AU2002338329B2 (en) * 2001-03-27 2006-09-07 The Regents Of The University Of California Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
WO2002079139A1 (de) 2001-03-29 2002-10-10 Basf Aktiengesellschaft Konjugierte ungesättigte glyceridgemische und verfahren zur ihrer herstellung
CN1523994A (zh) * 2001-05-23 2004-08-25 钱吉子 一种用于预防和/或治疗痴呆的以灵芝提取物、十八碳烯酰胺及其衍生物作为有效成分的组合物
ITMI20011483A1 (it) * 2001-07-11 2003-01-11 Res & Innovation Soc Coop A R Uso di composti come antagonisti funzionali ai recettori centrali deicannabinoidi
EP1406576B2 (en) * 2001-07-18 2011-06-29 Unilever PLC Hair and/or scalp treatment compositions
AU2002319286A1 (en) * 2001-07-18 2003-03-03 Unilever Plc Skin treatment
TWI250023B (en) * 2001-10-22 2006-03-01 Santen Pharmaceutical Co Ltd Pharmaceutical composition for itch treating agent
PL369952A1 (en) * 2001-11-14 2005-05-02 Schering Corporation Cannabinoid receptor ligands
EP1461027A4 (en) * 2001-12-07 2005-09-07 Univ Virginia Commonwealth TREATMENT OF NEOPLASIA
JPWO2003070277A1 (ja) 2002-02-19 2005-06-09 塩野義製薬株式会社 抗掻痒剤
NZ535349A (en) 2002-03-08 2007-01-26 Signal Pharm Inc JNK inhibitors with chemotherapeutic agents in a combination therapy for treating or preventing cancer and other proliferative disorders in refractory patients in particular
CA2478183C (en) 2002-03-12 2010-02-16 Merck & Co. Inc. Substituted amides
US20030232101A1 (en) * 2002-03-18 2003-12-18 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
UA79281C2 (en) * 2002-04-03 2007-06-11 Solvay Pharm Bv Stabilized composition comprising a natural cannabinoid compound and process for the preparation thereof
WO2004000807A1 (en) 2002-06-19 2003-12-31 Schering Corporation Cannabinoid receptor agonists
US20040018151A1 (en) * 2002-07-26 2004-01-29 Abood Mary E. Use of anandamide/cannabinoid receptor/acceptor agonists in als screening and treatment methods
MXPA05005512A (es) 2002-11-25 2005-07-25 Schering Corp Ligandos receptores canabinoides.
AR043633A1 (es) * 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
WO2005000829A1 (ja) 2003-06-26 2005-01-06 Takeda Pharmaceutical Company Limited カンナビノイド受容体調節剤
US7193096B2 (en) 2003-07-01 2007-03-20 Loders Croklaan Usa Llc Process for producing a conjugated di- or poly-unsaturated fatty acid of 12 to 24 carbon atoms or salt or ester thereof
MX2007000015A (es) * 2004-06-22 2007-03-07 Schering Corp Ligandos de receptor de canabinoide.
AU2005314021B2 (en) * 2004-12-09 2010-02-11 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
WO2008111296A1 (ja) 2007-03-09 2008-09-18 Kyoto University 角化の亢進に起因する皮膚疾患の予防及び治療のための医薬
IL187247A0 (en) * 2007-11-08 2008-12-29 Hadasit Med Res Service Novel synthetic analogs of sphingolipids
WO2009109973A2 (en) 2008-03-04 2009-09-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compounds and methods of treating obesity
EP2174642A1 (en) * 2008-10-10 2010-04-14 Unilever Plc, A Company Registered In England And Wales under company no. 41424 of Unilever House Use of Personal Care Composition
US20120277296A1 (en) 2009-07-23 2012-11-01 Sophie Lotersztajn Selective CB2 Receptor Agonists for Use in the Prevention or Treatment of Alcoholic Liver Disease
PL2475352T5 (pl) * 2009-09-07 2019-02-28 Epitech Group S.P.A. Kompozycja zawierająca palmitoiloetanoloamid poddany ultramikronizacji
CN102229527B (zh) 2009-12-14 2016-05-04 脂质营养品有限公司 工艺方法
US10019119B2 (en) 2010-09-09 2018-07-10 3M Innovative Properties Company Touch sensitive device with stylus support
EP2921167B1 (en) 2014-03-19 2016-08-17 EPITECH GROUP S.p.A. Pharmaceutical composition comprising palmitoylethanolamide and l-acetylcarnitine
ES2731729T3 (es) 2014-05-14 2019-11-18 Epitech Group S P A Uso de palmitoiletanolamida en combinación con opioides
EP2985037B1 (en) 2014-08-13 2017-06-21 EPITECH GROUP S.p.A. A pharmaceutical composition comprising palmitoylethanolamid and cytidine-diphosphocholine
WO2018071679A1 (en) 2016-10-13 2018-04-19 Carnot, Llc N-acylethanolamide derivatives and uses thereof
PH12018000227B1 (en) 2017-09-05 2019-03-11 Frimline Private Ltd A pharmaceutical composition for improving or preventing progression of chronic kidney disease
IT202000007831A1 (it) 2020-04-14 2021-10-14 Epitech Group S P A Adelmidrol per l’uso nel trattamento della fibrosi polmonare

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1252865B (it) * 1991-12-31 1995-06-28 Lifegroup Spa N-acilderivati di aminoalcooli attivi come autocoidi locali ed utilizzabili nella terapia dei processi autoimmuni
IT1252866B (it) * 1991-12-31 1995-06-28 Lifegroup Spa N-acilderivati di aminoalcooli con acidi policarbossilici atti alla modulazione dei mastociti nei processi infiammatori su base neuroimmunogenica
IT1271623B (it) * 1994-03-21 1997-06-04 Lifegroup Spa N-acilderivati di aminoalcoli con acidi monocarbossilici e bicarbossilici con attivita' neuroprotettiva nelle patologie neurologiche correlate ad eccitotossicita'

Also Published As

Publication number Publication date
ITMI942512A1 (it) 1996-06-14
IL116400A0 (en) 1996-03-31
CA2207850A1 (en) 1996-06-20
WO1996018391A2 (en) 1996-06-20
US5990170A (en) 1999-11-23
JP4216330B2 (ja) 2009-01-28
IT1271266B (it) 1997-05-27
AU4344296A (en) 1996-07-03
JPH11500411A (ja) 1999-01-12
WO1996018391A3 (en) 1996-08-15
WO1996018391B1 (en) 2001-04-05
EP0799033A1 (en) 1997-10-08
CA2207850C (en) 2009-08-04

Similar Documents

Publication Publication Date Title
ITMI942512A0 (it) Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli selettivamente attive sul recettore periferico dei cannabinoidi
ITMI942513A0 (it) Ammidi di acidi mono e bicarbossilici con amminoalcoli selettivamente attive sul recettore periferico dei cannabinoidi
TR199600481A2 (tr) Tedavi edici amidler.
DE69629255D1 (de) Herzunterstützungsvorrichtung
NO960414L (no) Anvendelse av fenylcykloheksylkarboksylsyreamider
PT951465E (pt) Amidas de alfa-aminoacidos preparacao das mesmas e utilizacao terapeutica das mesmas
DE59505722D1 (de) Ultraschall-schweissverfahren und ultraschall-schweissvorrichtung
ITMI921851A0 (it) Ammidi acriliche farmacologicamente attive
DE29517853U1 (de) Flüssigkeits-Spritzkopf
ITMI942358A0 (it) Peptidi ad attivita' antiinfiammatoria
DE69722178T2 (de) Therapeutischer wirkstoff für augenerkrankungen
FR2584924B3 (fr) Tuyere perfectionne pour baignoires d'hydromassage
NO962385L (no) Terapeutiske amider
MA26570A1 (fr) Forme active d'une proteine hedgehog, procede pour la produire, et son utilisation therapeutique
NO932731L (no) Nye isobutylsubstituerte metansulfonyl-kinolylmetoksy-fenyl-cykloalkyl-eddiksyreamider
KR970019229U (ko) 모니터의 스피커 홀더 고정 구조
KR950012456U (ko) 브이씨알의 텐션 제어장치
TH30422B (th) เดลต้า-อะมิโน-แกมมา-ไฮดรอกซี-โอเมก้า-อะริล-อัลคาโนอิคแอซิดเอไมด์ชนิดใหม่
KR960025642U (ko) 브이씨알의 음성콘트롤 헤드의 커넥터 장치
KR940001843U (ko) Ldp의 틸트 서어보 장치
KR940027446U (ko) 브이씨알의 텐션 제어장치
KR950009753U (ko) 브이씨알의 텐션 제어장치
IT1277951B1 (it) Processo e dispositivo per l'attivazione di elettrodi atti alla realizzazione di dispositivi elettrocromici
KR960022161U (ko) 관리기의 조향장치
ITMI941731A0 (it) Nuovi nitro-inibitori aventi attivita' anti-infiammatoria

Legal Events

Date Code Title Description
0001 Granted